中药药源性心脏毒性研究进展  

Research Progress of Chinese Materia Medica-induced Cardiotoxicity

作　　者：潘校琦 阎博华 周杰 曹小玉 彭成[1] PAN Xiaoqi;YAN Bohua;ZHOU Jie;CAO Xiaoyu;PENG Cheng(State Key Laboratory of Southwestern Chinese Medicine Resources,School of Pharmacy,Chengdu University of Traditional Chinese Medicines,Chengdu 611137,China)

机构地区：[1]成都中医药大学药学院西南特色中药资源重点实验室,四川成都611137

出　　处：《药学进展》2020年第10期730-742,共13页Progress in Pharmaceutical Sciences

基　　金：国家自然科学基金重点项目(No.81630101);国家自然科学基金重大项目(No.81891010,No.81891012);国家自然科学基金青年项目(No.82004056);四川省科技计划重点研发项目(No.2018JZ0081)。

摘　　要：药源性心脏毒性是药物临床应用的主要安全性问题之一,也是人们关注的热点。目前,化学性药物致心脏毒性已有较为规范的评价体系。但中药药源性心脏毒性影响因素多、作用机制复杂、毒性反应多样,缺乏特异性评价指标,现有评价方法并不完全适用于中药。因此,建立中药药源性心脏毒性评价体系已成为当前我国中药新药开发、评审、监管亟需解决的重要问题。综述中药药源性心脏毒性的主要影响因素、作用机制及监测手段,并提出中药致心脏毒性的最新研究技术,旨在为我国中药安全性评价提供参考。Drug-induced cardiotoxicity,one of the major safety concerns in the clinical application of drugs,has aroused our wide attention.Currently,there have been standard evaluation systems for cardiotoxicity caused by chemical drugs,however,existing evaluation methods are not fully applicable to Chinese materia medica(CMM)-induced cardiotoxicity,which can be affected by many factors with complex toxicity mechanisms,diverse toxic effects and lack of specific evaluation indicators.The establishment of CMM-induced cardiotoxicity evaluation system has become an important issue,which urgently needs to be solved in the discovery,approval and regulation of new drugs in China.This article reviews the main factors for the cardiotoxicity of CMM,the mechanisms of cardiotoxicity,the general monitoring indicators,and the latest research techniques for cardiotoxicity caused by CMM,which aims to provide reference for the safety evaluation of CMM.

关 键 词：中药 心脏毒性 新药开发 安全性评价 

分 类 号：R285.1[医药卫生—中药学]